Dipna Pharmachem informs about outcome of board meeting

Dipna Pharmachem Ltd. | Trading | Miscellaneous | BSE: 543594 | NSE:

29 Nov 2025 Evaluate

With reference to the Board Meeting held on 9th September, 2025 and 12th September, 2025 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dipna Pharmachem has informed that the Board of Directors of the Company, at its meeting held today, i.e., Saturday, 29th November, 2025, at the registered office of the Company situated at A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India - 380 055, which commenced at 11:30 AM and concluded at 12:10 PM, have considered and approved the allotment of 22,44,000 fully Paid-up Equity Shares pursuant to conversion of 22,44,000 convertible warrants (Out of a total 5,80,32,500 Convertible Warrants) having a face value of Rs 10.00 each, at an issue price of Rs 13.05 each (including premium of Rs 03.05 each), on receipt of the balance amount, i.e., 75.00% of the issue price per warrant, from Ashok Dilipkumar Jain and Kajal Ashok Jain, the allottee(s) belonging to the ‘Non-Promoter Category’, upon exercise of option to convert the Warrants into Equity Shares in accordance with the provisions of SEBI (ICDR) Regulations, 2018. Details of allotment as mentioned in Annexure - I. The allotment has been made for cash, upon receipt of the remaining exercise price of Rs. 9.79 each (being an amount equivalent to 75.00% of the warrant exercise price of Rs 13.05 each), aggregating to Rs 2,19,63,150.00. The Equity Shares allotted upon the exercise of warrants on a preferential basis shall rank pari-passu with the existing equity shares of the Company in all respects. Consequent to the aforesaid conversion, the paid-up equity share capital of the Company has increased from Rs 24,04,52,500.00 consisting of 2,40,45,250 equity shares having face value of Rs 10.00 each to Rs. 26,28,92,500.00 consisting of 2,62,89,250 Equity Shares having face value of Rs 10.00 each. The application for listing and trading approval of the newly issued and allotted equity shares will be made to the Stock Exchange in due course. Further, the requisite information regarding the issuance of securities under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 as mentioned in Annexure - II.

The above information is a part of company’s filings submitted to BSE.

Dipna Pharma. Share Price

8.20 -0.11 (-1.32%)

08-May-2026 16:59 View Price Chart

Peers

Company Name	CMP
Redington	222.80
Adani Enterprises	2505.65
Amrapali Industries	18.21
Rashi Peripheral	530.50
PDS	300.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.